Bicycle Therapeutics earnings release, July 30, 2026
Bicycle Therapeutics Reports Recent Business
Progress and Second Quarter 2026 Financial Results
Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities
Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.
Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030
CAMBRIDGE, England & BOSTON, July 30,
2026 – Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates.
“We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our next-generation Bicycle conjugate pipeline, including Bicycle®
Radioconjugates (BRC®), leaves us well capitalized to pursue our mission to help patients to not only live longer, but also live well,” said Bicycle CEO Kevin Lee, Ph.D. “The encouraging data we presented during the quarter continue to deepen our belief in the potential of our technology to deliver oncology therapeutics with a superior benefit/risk profile against high-value targets like EphA2 and Nectin-4, the former being historically considered undruggable using antibody-based approaches. We believe this profile provides a strong rationale for developing nuzefatide in recurrent pancreatic cancer, where we successfully dosed our first patient in the ongoing Phase 2 trial in April. We remain on track to begin the Phase 1 trial for BT1702, our MT1-MMP targeting
BRC, in 2027, backed by compelling human imaging data validating the targeting precision and translatability of our Bicycle® technology.”
Dr Lee added: “It is an honor to welcome world-renowned oncologist Professor Thomas Powles to our Clinical Advisory Board. His deep clinical insights and distinguished leadership in urothelial cancers will be instrumental as we accelerate our efforts to deliver precision-targeted therapies for patients.”
Second Quarter 2026 and Recent Events
Altogether, Bicycle Therapeutics believes that these data underscore the therapeutic potential for nuzefatide in EphA2-expressing cancers, including pancreatic cancer.
Bicycle Therapeutics is actively enrolling patients in a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent
PDAC. The first patient was successfully dosed in April 2026 at the 8mg/m²
Q2W preferred dose for the trial.
Bicycle Therapeutics continues to advance its emerging radioligand pipeline, with the initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP targeting BRC, expected in 2027.
Across all patients, the safety and tolerability profile was consistent with other zelenectide data to date. No new safety signals were observed and there were no Grade 4 or Grade 5 zelenectide-related AEs of clinical interest reported.
Second Quarter 2026 Financial Results
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle®
Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle®
Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.
Bicycle Therapeutics is headquartered in Cambridge,
UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.
Forward Looking Statements
Financial statements
Income Statement
Three Months Ended — (Unaudited) (in thousands)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Collaboration revenue | 629 | 2,920 | 1,516 | 12,897 | |
| Operating expenses: | Research and development | 41,160 | 71,029 | 90,061 | 130,087 |
| Operating expenses: | General and administrative | 14,028 | 18,493 | 31,496 | 39,616 |
| Operating expenses: | Total operating expenses | 55,188 | 89,522 | 121,557 | 169,703 |
| Operating expenses: | Loss from operations | -54,559 | -86,602 | -120,041 | -156,806 |
| Other income (expense): | Interest and other income | 4,360 | 7,473 | 9,237 | 15,887 |
| Other income (expense): | Interest expense | -44 | -54 | -92 | -105 |
| Other income (expense): | Total other income, net | 4,316 | 7,419 | 9,145 | 15,782 |
| Other income (expense): | Net loss before income tax provision | -50,243 | -79,183 | -110,896 | -141,024 |
| Other income (expense): | Provision for (benefit from) income taxes | 90 | -231 | 262 | -1,318 |
| Other income (expense): | Net loss | -50,333 | -78,952 | -111,158 | -139,706 |
| Other income (expense): | Net loss per share, basic and diluted | -0.72 | -1.14 | -1.59 | -2.02 |
| Other income (expense): | Weighted average ordinary shares outstanding, basic and diluted | 69,804,828 | 69,252,009 | 69,744,485 | 69,224,629 |
Balance Sheet
December 31, — (Unaudited) (in thousands)
| June 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| Cash and cash equivalents | 510,052 | 628,110 |
| Working capital | 527,601 | 625,901 |
| Total assets | 606,578 | 717,597 |
| Total shareholders’ equity | 510,255 | 609,977 |
Full release
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,”
“expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”,
“promising”, “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of nuzefatide pevedotin, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and the potential development of nuzefatide pevedotin in a number of cancers, including pancreatic cancer; the progress of Bicycle
Therapeutics’ clinical trials, reporting data from Bicycle Therapeutics’ clinical trials, including for nuzefatide pevedotin, the timing of EphA2 human imaging data and updates on future clinical development plans for nuzefatide pevedotin; the potential of EphA2... (truncated)positive properties of Bicycle® radioligand molecules for radiopharmaceutical use; the development of the Bicycle® radioligands pipeline, including BRCs and BIAs; communications with and feedback from the FDA and other regulatory agencies; Bicycle Therapeutics’ expected financial runway; and the use of Bicycle Therapeutics’ technology through various partnerships to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the workforce reduction may take longer or result in more significant charges or cash expenditures than anticipated or otherwise negatively impact Bicycle Therapeutics’ and its business plans during and after the period during which the workforce reduction is being executed; uncertainties related to the benefits of the strategic reprioritization; uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its technology or partnerships; the risk that Bicycle Therapeutics may not achieve any of its clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics’ projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle Therapeutics’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 17, 2026, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Bicycle Therapeutics plc
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
Balance Sheets Data
(In thousands)
(Unaudited)
Investors:
Matthew DeYoung
Argot Partners ir@bicycletx.com
212-600-1902
Media:
Argot Partners media@bicycletx.com